Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.

Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, Huber V, Parmiani G, Generoso L, Santinami M, Borghi M, Fais S, Bellone M, Rivoltini L.

Cancer Res. 2012 Jun 1;72(11):2746-56. doi: 10.1158/0008-5472.CAN-11-1272. Epub 2012 May 16.

2.

HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.

Fauquembergue E, Toutirais O, Tougeron D, Drouet A, Le Gallo M, Desille M, Cabillic F, de La Pintière CT, Iero M, Rivoltini L, Baert-Desurmont S, Leprince J, Vaudry H, Sesboué R, Frébourg T, Latouche JB, Catros V.

J Immunother. 2010 May;33(4):402-13. doi: 10.1097/CJI.0b013e3181d366da.

PMID:
20386466
3.

pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.

De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Della Mina P, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S.

Int J Cancer. 2010 Jul 1;127(1):207-19. doi: 10.1002/ijc.25009.

4.

Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?

Iero M, Filipazzi P, Castelli C, Belli F, Valdagni R, Parmiani G, Patuzzo R, Santinami M, Rivoltini L.

Cancer Immunol Immunother. 2009 Jul;58(7):1159-67. doi: 10.1007/s00262-008-0610-6. Epub 2008 Nov 8.

PMID:
18998128
5.

More insights into the immunosuppressive potential of tumor exosomes.

Huber V, Filipazzi P, Iero M, Fais S, Rivoltini L.

J Transl Med. 2008 Oct 30;6:63. doi: 10.1186/1479-5876-6-63. No abstract available.

6.

Tumour-released exosomes and their implications in cancer immunity.

Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L.

Cell Death Differ. 2008 Jan;15(1):80-8. Epub 2007 Oct 12. Review.

7.

Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L.

J Clin Oncol. 2007 Jun 20;25(18):2546-53.

PMID:
17577033
8.

Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.

Iero M, Squarcina P, Romero P, Guillaume P, Scarselli E, Cerino R, Carrabba M, Toutirais O, Parmiani G, Rivoltini L.

Cancer Immunol Immunother. 2007 Dec;56(12):1979-91. Epub 2007 Jun 13.

PMID:
17564703
9.

Tumor-released microvesicles as vehicles of immunosuppression.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L.

Cancer Res. 2007 Apr 1;67(7):2912-5. Review.

10.

Vaccination therapy in prostate cancer.

Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G, Rivoltini L.

Cancer Immunol Immunother. 2007 Apr;56(4):429-45. Epub 2006 Oct 10. Review.

PMID:
17031640
11.

Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.

Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Rivoltini L.

Gastroenterology. 2005 Jun;128(7):1796-804.

PMID:
15940614
12.

Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?

Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G.

Expert Opin Biol Ther. 2005 Apr;5(4):463-76. Review.

PMID:
15934826

Supplemental Content

Support Center